EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will take part. The main goal …

This study tests a personalized vaccine (made from each patient's unique tumor markers) combined with the immunotherapy drug durvalumab for people with extensive-stage small cell lung cancer. The goal is to see if this combination is safe and can help slow cancer growth. Only 6 p…

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The treatment combines low-dose radiation, standard chemotherapy, and an immunotherapy drug called serplulimab. The goal is to see if this combination c…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced small cell lung cancer that has spread and has been treated before. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to see if it can shrink tumors…

This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The treatment combines low-dose radiation with the immunotherapy drug durvalumab and standard chemotherapy. The goal was to see if this combination cou…

This study aimed to test a combination of two drugs, tarlatamab and sacituzumab govitecan, in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to see if the combination w…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The goal is to see if the drug can shrink tumors or stop them from growing. This is a Phase 2a trial, meaning it's still earl…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…

This early-stage study aimed to test a combination of low-dose radiation, chemotherapy, and two immunotherapy drugs (toripalimab and tifcemalimab) as a first treatment for extensive-stage small cell lung cancer. The goal was to check safety and find the best dose. However, the st…

This study tests a new drug called serplulimab combined with chemotherapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. It compares this new combination to another approved drug (atezolizumab) plus the same chemotherapy. The goal is to see …

This study tests an experimental drug called MGC018 in 9 adults with extensive-stage small-cell lung cancer that has returned or not responded to treatment. Participants receive the drug by IV every 28 days. The main goal is to see if the drug shrinks tumors in at least 25% of pa…

This study tests a new drug called BNT327 combined with chemotherapy for people with advanced small-cell lung cancer. It includes patients who have not been treated before and those whose cancer came back after earlier treatments. The goal is to see if the combination is safe and…

This study tests a new drug called tarlatamab combined with standard chemotherapy and an immunotherapy for people with extensive stage small cell lung cancer who have not had prior treatment. The main goals are to check safety and side effects, and to see how well the combination…

This study tests a new drug, [177Lu]Lu-DOTA-TATE, combined with standard chemotherapy and immunotherapy for people newly diagnosed with extensive stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 adults wil…